Skip to content

Ketamine: all studies

Page 97 of 448: studies 961 to 970 of 4,475, newest first. Back to the ketamine overview

Research

Ketamine administration during adolescence impairs synaptic integration and inhibitory synaptic transmission in the adult dentate gyrus.

Progress in Neurobiology March 1, 2025 Odra Santander, Sebastián B Arredondo, Francisca García-Rojas et al. 3 citations

Ketamine administration during adolescence affects cognitive performance; however, its long-term impact on synaptic function and neuronal integration in the hippocampus a brain region critical for cognition remains unclear. Using functional and molecular analyses, we found that chronic ketamine administration during adolescence exerts long-term effects on synaptic integration, expanding the...

DOI: 10.1016/j.pneurobio.2025.102718 (opens in new tab) Full text (opens in new tab) Ketamine Adolescence Dentate gyrus Inhibitory synaptic transmission +6

The ketamine chameleon: history, pharmacology, and the contested value of experience.

Expert Review of Clinical Pharmacology March 1, 2025 Danny Diep, Sara de la Salle, Julien Thibault Lévesque et al. 8 citations

Since its synthesis in 1962, ketamine has been widely used in diverse medical contexts, from anesthesia to treatment-resistant depression. However, interpretations of ketamine's subjective effects remain polarized. Biomedical frameworks typically construe the drug's experiential effects as dissociative or psychotomimetic, while psychedelic paradigms emphasize the potential therapeutic merits of...

Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation.

Psychiatry Research March 1, 2025 Tung-Ping Su, Li-Kai Cheng, Pei-Chi Tu et al. 6 citations

Ketamine is a dissociative drug used for the treatment of depression. However, the neurofunctional mechanism underlying the antidepressant effect of ketamine remains unknown. According to previous research, low-dose ketamine affects large-scale brain networks, including default-mode and salient networks. A total of 43 patients with treatment-resistant depression (TRD) and suicidal ideation (SI)...

(2R, 6R)-hydroxynorketamine alleviates postictal depression induced by pilocarpine through modulating LRP4 expression in hippocampal astrocytes.

Epilepsy & Behavior March 1, 2025 Meiying Zhang, Liting Zheng, Jixing Chen et al.

Postictal depression is a common comorbidity in epilepsy, yet effective treatments remain limited. While ketamine is well-known for its antidepressant properties, its role in postictal depression has not been thoroughly investigated. In this study, we utilized a pilocarpine-induced status epilepticus (SE) mouse model and found that depression-like behavior does not appear within a day after SE...

DOI: 10.1016/j.yebeh.2025.110294 (opens in new tab) Full text (opens in new tab) Postictal depression Status epilepticus se Depression treatment Epilepsy complications +2

Effects of Chronic Social Isolation Stress and Alcohol on the Reinforcing Properties of Ketamine in Male and Female Rats.

eNeuro March 1, 2025 Sarah D Jennings, Devin P Hagarty, Jordan Logue et al. 1 citation

While ketamine, an NMDA receptor antagonist, is effective in treating major depression, studies have not addressed the safety of repeated ketamine infusions in depressed patients with comorbid alcohol use disorder (AUD). In this study, we aimed to determine whether a history of chronic social isolation and alcohol exposure alter the reinforcing properties of ketamine in male and female rats....

The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.

CNS Neuroscience & Therapeutics March 1, 2025 Zerui You, Xiaofeng Lan, Chengyu Wang et al. 1 citation

Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action. The study included 40 MDD patients treated with ketamine in the discovery cohort and 24...

DOI: 10.1111/cns.70324 (opens in new tab) Full text (opens in new tab) Major depressive disorder Mental health research Metabolic biomarkers Metabolomic +3

Treadmill Exercise Training Ameliorates Apoptotic Cells and DNA Oxidation in the Cerebral Cortex of Rats Exposed to Chronic Ketamine Abuse.

Addiction Biology March 1, 2025 Salar Sabziparvar, Kazem Khodaei, Javad Tolouei Azar 1 citation

Ketamine abuse damages brain function and structure, increasing reactive oxygen species and apoptosis in the cerebral cortex, but moderate-intensity continuous training (MICT) can enhance antioxidant defences and reduce apoptosis. Therefore, we aimed to answer whether MICT can reduce the side effects of chronic ketamine abuse. 24 Wistar rats were split into control (CON), ketamine abuse (KET),...

Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.

Psychiatry Research March 1, 2025 Juliana Lima Constantino, Martijn Godschalk, Jens H van Dalfsen et al. 14 citations

Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to...

Repeated ketamine doses elevate superoxide dismutase activity in a pharmacological model of schizophrenia-like phenotypes in mice

INNOSC Theranostics and Pharmacological Sciences February 28, 2025 Yusuf Usman, Adegbuyi Oladele Aderibigbe, Fatai Adewale Fehintola

This study evaluated behavioral phenotypes and superoxide dismutase (SOD) enzymatic activity in a repeated sub-anesthetic dose of ketamine (KET) administered to model schizophrenia in an animal study. The animals were divided into three (3) experimental groups. The KET alone group received sub-anesthetic dose of KET (20 mg/kg) for 14 consecutive days. The control group vehicle (VEH) received...

Ketamine en esketamine bij bipolaire depressie

February 27, 2025 Kristin Raj

Ketamine en esketamine tonen veelbelovende resultaten bij bipolaire depressie: 40% van de patiënten reageert positief op behandeling tweemaal per week. Volledige remissie wordt bereikt bij 13%. Tijdens de intensieve behandelfase traden geen acute manische switches op, maar 30% van de patiënten ervoer een hypomane of manische episode tijdens de onderhoudsfase. De meeste episoden waren licht van...